Renaissance Technologies LLC Acquires 55,300 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR)

Renaissance Technologies LLC boosted its position in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 4.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,237,600 shares of the company's stock after acquiring an additional 55,300 shares during the period. Renaissance Technologies LLC owned 0.90% of Vir Biotechnology worth $9,084,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in VIR. Invesco Ltd. grew its holdings in Vir Biotechnology by 0.6% during the 4th quarter. Invesco Ltd. now owns 398,772 shares of the company's stock worth $2,927,000 after acquiring an additional 2,574 shares during the period. Polymer Capital Management US LLC bought a new stake in Vir Biotechnology in the fourth quarter valued at about $101,000. Aster Capital Management DIFC Ltd lifted its stake in Vir Biotechnology by 19,214.6% in the fourth quarter. Aster Capital Management DIFC Ltd now owns 34,380 shares of the company's stock valued at $252,000 after buying an additional 34,202 shares during the period. ExodusPoint Capital Management LP bought a new position in Vir Biotechnology during the fourth quarter worth about $1,812,000. Finally, Headlands Technologies LLC grew its position in shares of Vir Biotechnology by 183.3% during the 4th quarter. Headlands Technologies LLC now owns 32,432 shares of the company's stock worth $238,000 after buying an additional 20,984 shares during the period. Institutional investors own 65.32% of the company's stock.

Vir Biotechnology Price Performance

NASDAQ:VIR traded up $0.31 during trading hours on Wednesday, reaching $6.11. 360,687 shares of the stock were exchanged, compared to its average volume of 1,334,593. The stock has a market cap of $837.94 million, a PE ratio of -1.56 and a beta of 1.14. Vir Biotechnology, Inc. has a twelve month low of $4.95 and a twelve month high of $14.45. The firm has a 50 day moving average of $7.11 and a 200 day moving average of $8.08.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last announced its earnings results on Wednesday, February 26th. The company reported ($0.76) EPS for the quarter, topping the consensus estimate of ($0.85) by $0.09. Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. The business had revenue of $12.37 million during the quarter, compared to analysts' expectations of $8.14 million. Equities research analysts anticipate that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. The Goldman Sachs Group cut their target price on shares of Vir Biotechnology from $28.00 to $21.00 and set a "buy" rating on the stock in a report on Thursday, April 17th. HC Wainwright reissued a "buy" rating and set a $110.00 target price on shares of Vir Biotechnology in a research note on Friday, February 28th. Barclays lifted their price target on shares of Vir Biotechnology from $26.00 to $31.00 and gave the company an "overweight" rating in a research note on Friday, February 28th. JPMorgan Chase & Co. upped their price target on shares of Vir Biotechnology from $10.00 to $14.00 and gave the company a "neutral" rating in a report on Thursday, January 9th. Finally, Morgan Stanley upgraded shares of Vir Biotechnology from an "equal weight" rating to an "overweight" rating and raised their price objective for the stock from $10.00 to $20.00 in a report on Thursday, January 9th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, Vir Biotechnology presently has an average rating of "Moderate Buy" and an average price target of $33.57.

Insider Buying and Selling

In other news, Director George A. Scangos sold 10,964 shares of the business's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $9.81, for a total transaction of $107,556.84. Following the transaction, the director now directly owns 708,295 shares in the company, valued at $6,948,373.95. The trade was a 1.52 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Backer Marianne De sold 79,712 shares of the firm's stock in a transaction dated Thursday, April 3rd. The shares were sold at an average price of $5.95, for a total transaction of $474,286.40. Following the completion of the sale, the chief executive officer now owns 769,505 shares of the company's stock, valued at $4,578,554.75. This trade represents a 9.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 99,611 shares of company stock worth $663,525. Corporate insiders own 15.60% of the company's stock.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).